Michael Badruddoja - Concepedia

Author

Michael Badruddoja

Also Known As

M. A. Badruddoja, M. Badruddoja, Michael A Badruddoja, Michael A. Badruddoja, Michael Badruddoja, Ricardo Ayala, S. Grossman

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

Duke Medical Center Duke University Hospital Duke University Center for Neurosciences University of California, San Francisco

About

Michael Badruddoja is an author at Duke Medical Center specializing in medicine, glioma, and neuro-oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	144
2	Health Sciences	2	2	38
3	Immunology	2	2	28
4	Cell Biology	1	1	50
5	Clinical Immunology	1	1	12

Michael Badruddoja

Publications

Citations

H-Index

Page 1

	Year	Citations
Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme David A. Reardon, Merrill J. Egorin, Jennifer A. Quinn, Journal of Clinical Oncology	2005	330
Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results David A. Reardon, Gamal Akabani, R. Edward Coleman, Journal of Clinical Oncology	2005	198
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma David A. Reardon, Jennifer A. Quinn, James J. Vredenburgh, Cancer	2004	116
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Cancer	2005	76
Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRIcerebral blood volume maps Michael Badruddoja, Hendrikus G. J. Krouwer, Scott D. Rand, Neuro-Oncology	2003	71
Phase 2 trial of BCNU plus irinotecan in adults with malignantglioma David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Neuro-Oncology	2004	51
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. David A. Reardon, Jennifer A. Quinn, Gamal Akabani, PubMed	2006	51
Expanded analysis of high-grade astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1 Patrick J. Cimino, Courtney Ketchum, Rust Turakulov, Acta Neuropathologica Neuro-oncologyTumoral PathologyPediatric Brain TumorsGliomaPiloid Features	2022	50
Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma Michael Badruddoja, Marjorie Pazzi, Abhay Sanan, Cancer Chemotherapy and Pharmacology Neuro-oncologyGliomaMedicineAdult PatientsMetronomic Therapy	2017	29
Ongoing Clinical Trials Joanna Clarke, Marguerite Ennis, Kathleen R. Lamborn, Neuro-Oncology Clinical Trial ManagementClinical EndpointClinical TrialsRandomized Controlled TrialMedicine	2010	22

Page 1